Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab

Hyperprogression is a pattern of accelerated tumor growth noted uncommonly after the use of immune checkpoint inhibitors in some patients. We present a 56-year-old female with gastroesophageal junction (GEJ) adenocarcinoma who was initially treated with neoadjuvant radiation and chemotherapy with ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Sama, Shashank, Hadfield, Matthew J, Lopetegui Lia, Nerea, Vredenburgh, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684307/
https://www.ncbi.nlm.nih.gov/pubmed/31410344
http://dx.doi.org/10.7759/cureus.4862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684307/
https://www.ncbi.nlm.nih.gov/pubmed/31410344
http://dx.doi.org/10.7759/cureus.4862

Ejemplares similares